Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00566696 · FLOW

Participant flow

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies · Source last updated 2020-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.
    id
    FG000
    title
    High-Risk Hematologic Malignancies
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Met Exclusion Criteria
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Muromonab not available
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Health Status Change
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    5. reasons
      1. group Id
        FG000
        num Subjects
        37
      type
      Non-Patient Donors
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        73
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        31
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        42
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
There were 73 enrollments at St. Jude Children's Research Hospital between 12/2007 and 12/2013. Of the 73, 37 were non-patient donors who did not receive therapeutic intervention, and therefore, no outcome data was collected.
Complete source fields
groups
  1. description
    Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.
    id
    FG000
    title
    High-Risk Hematologic Malignancies
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Met Exclusion Criteria
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Muromonab not available
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Health Status Change
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    5. reasons
      1. group Id
        FG000
        num Subjects
        37
      type
      Non-Patient Donors
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        73
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        31
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        42
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
There were 73 enrollments at St. Jude Children's Research Hospital between 12/2007 and 12/2013. Of the 73, 37 were non-patient donors who did not receive therapeutic intervention, and therefore, no outcome data was collected.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice